17 小时
Zacks.com on MSNWhy Cencora (COR) is a Top Growth Stock for the Long-TermFor new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Cencora, a global healthcare company, has expanded its Sure Supply Program to include 200 critical medications, including several oncology treatments, in response to ongoing drug shortages.
Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...
For the quarter ended December 2024, Cencora (COR) reported revenue of $81.49 billion, up 12.8% over the same period last year. EPS came in at $3.73, compared to $3.28 in the year-ago quarter.
Cencora, Inc. (NYSE:COR – Get Free Report) has received an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the firm, Marketbeat Ratings reports.
Mauch emphasized the strategic alignment of the RCA acquisition with Cencora’s pharmaceutical-centric strategy. CFO James Cleary noted, "Cencora delivered strong results in the first quarter ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果